ClinicalTrials.Veeva

Menu

Prevalance of non_ Alcoholic Fatty Liver Diseases in Patient With Inflammatory Bowel Diseases Attending Assiut University Hospitals

A

Assiut University

Status

Unknown

Conditions

Inflammatory Bowel Disease Patients

Study type

Observational

Funder types

Other

Identifiers

NCT04328259
NAFLD in patient of IBD

Details and patient eligibility

About

To assess the prevalance of non_alcoholic fatty liver diseases in inflammatory bowel disease patients and its relation to type of treatment given and disease severity

Full description

Inflammatory bowel diseases (IBD) including Crohns disease (CD) and ulcerative colitis (UC) are chronic relapsing disorders that often require long-term therapy and follow up .

They are recognized for their complex pathophysiology that involves innate immune system deregulation and altered microbiome in genetically predisposed individuals. Non-alcoholic fatty liver disease (NAFLD) includes a wide spectrum of disorders, ranging from hepatic steatosis (NAFL) to non-alcoholic steatohepatitis (NASH). NAFLD patients are at high risk for liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Also NAFLD is typically associated with altered metabolism and metabolic syndrome (MetS).

Enrollment

30 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Crohn's disease (CD) patients
  • ulcerative colitis (UC) patients

Exclusion criteria

  • diabetic patients
  • BMI equal and more than 30.0-34.9(class I obesity)

Trial contacts and locations

0

Loading...

Central trial contact

Mohamed A Ali, Assistant professor; Shymaa A Ahmed, Resident

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems